Aurobindo Pharma Ltd
NSE:AUROPHARMA
Aurobindo Pharma Ltd
NSE:AUROPHARMA
Price:
1 159
INR
0.73%
Market Cap:
₹673.1B
Cash Flow Statement
Cash Flow Statement
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd
Currency: INR
| Mar-2021 | Sep-2021 | Mar-2022 | Sep-2022 | Mar-2023 | Sep-2023 | Mar-2024 | Sep-2024 | Mar-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | |||||||||||
| Net Income |
73 436
|
70 516
|
33 727
|
25 898
|
26 125
|
32 978
|
43 800
|
50 237
|
50 663
|
50 177
|
|
| Depreciation & Amortization |
10 554
|
11 164
|
11 265
|
11 302
|
12 446
|
14 110
|
15 217
|
15 641
|
16 494
|
16 979
|
|
| Stock-Based Compensation |
0
|
0
|
0
|
0
|
0
|
0
|
89
|
0
|
107
|
0
|
|
| Other Non-Cash Items |
(27 180)
|
(29 087)
|
2 176
|
3 867
|
3 419
|
1 464
|
(254)
|
1 443
|
1 847
|
4 923
|
|
| Cash Taxes Paid |
12 853
|
14 749
|
12 582
|
9 944
|
7 172
|
9 684
|
17 666
|
18 781
|
17 314
|
17 600
|
|
| Cash Interest Paid |
481
|
346
|
185
|
336
|
1 112
|
1 982
|
2 507
|
3 467
|
4 203
|
3 930
|
|
| Change in Working Capital |
(23 296)
|
(23 599)
|
2 964
|
11 173
|
(18 058)
|
(28 607)
|
(34 417)
|
(51 447)
|
(29 752)
|
(10 505)
|
|
| Cash from Operating Activities |
33 513
N/A
|
28 993
-13%
|
50 132
+73%
|
52 240
+4%
|
23 932
-54%
|
19 945
-17%
|
24 345
+22%
|
15 873
-35%
|
39 253
+147%
|
61 573
+57%
|
|
| Investing Cash Flow | |||||||||||
| Capital Expenditures |
(18 738)
|
(27 491)
|
(27 046)
|
(23 711)
|
(27 204)
|
(36 025)
|
(35 615)
|
(23 627)
|
(25 196)
|
(32 162)
|
|
| Other Items |
24 725
|
23 225
|
(5 069)
|
(24 983)
|
(12 574)
|
689
|
(6 945)
|
4 597
|
6 438
|
(1 748)
|
|
| Cash from Investing Activities |
5 987
N/A
|
(4 267)
N/A
|
(32 116)
-653%
|
(48 695)
-52%
|
(39 778)
+18%
|
(35 336)
+11%
|
(42 560)
-20%
|
(19 029)
+55%
|
(18 758)
+1%
|
(33 910)
-81%
|
|
| Financing Cash Flow | |||||||||||
| Net Issuance of Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(9 302)
|
(9 302)
|
0
|
|
| Net Issuance of Debt |
(10 824)
|
(10 839)
|
(26 871)
|
(5 872)
|
23 651
|
22 694
|
13 147
|
15 943
|
14 939
|
(7 200)
|
|
| Cash Paid for Dividends |
(2 343)
|
(2 491)
|
(2 637)
|
(4 391)
|
(4 395)
|
0
|
(2 636)
|
(2 643)
|
(10)
|
(2 326)
|
|
| Other |
(481)
|
(346)
|
(185)
|
(336)
|
(1 112)
|
(1 981)
|
(2 507)
|
(3 467)
|
(4 428)
|
(4 155)
|
|
| Cash from Financing Activities |
(13 648)
N/A
|
(13 676)
0%
|
(29 693)
-117%
|
(10 599)
+64%
|
18 144
N/A
|
18 951
+4%
|
8 004
-58%
|
530
-93%
|
1 198
+126%
|
(13 680)
N/A
|
|
| Change in Cash | |||||||||||
| Effect of Foreign Exchange Rates |
(21)
|
48
|
2
|
(11)
|
(1)
|
47
|
142
|
300
|
91
|
69
|
|
| Net Change in Cash |
25 831
N/A
|
11 098
-57%
|
(11 675)
N/A
|
(7 065)
+39%
|
2 298
N/A
|
3 608
+57%
|
(10 068)
N/A
|
(2 326)
+77%
|
21 784
N/A
|
14 052
-35%
|
|
| Free Cash Flow | |||||||||||
| Free Cash Flow |
14 775
N/A
|
1 502
-90%
|
23 086
+1 437%
|
28 529
+24%
|
(3 272)
N/A
|
(16 080)
-391%
|
(11 270)
+30%
|
(7 753)
+31%
|
14 057
N/A
|
29 411
+109%
|
|
Switch to:
Switch to:
See Also
Discover More
